The briefing
The report says targeted cancer treatments are increasingly paired with immunotherapies and chemotherapies to improve outcomes across tumor types. It discusses emerging strategies—such as efforts involving PP2A—and how these trends may reshape development pipelines.
Original headline
Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built